Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A LONG-TERM SAFETY AND EFFICACY STUDY OF CD5789 50 microg/g CREAM IN SUBJECTS WITH ACNE VULGARIS

Trial Profile

A LONG-TERM SAFETY AND EFFICACY STUDY OF CD5789 50 microg/g CREAM IN SUBJECTS WITH ACNE VULGARIS

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 18 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Trifarotene (Primary)
  • Indications Acne vulgaris
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Galderma
  • Most Recent Events

    • 31 May 2017 Status changed from active, no longer recruiting to completed.
    • 29 Mar 2017 This trial was completed in Hungary (end date: 2017-02-23), according to European Clinical Trials Database.
    • 19 Mar 2017 This trial ha been completed in Czech Republic (End date:2017-02-23) as per European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top